These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1318 related articles for article (PubMed ID: 31099553)

  • 1. Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing.
    Wilbie D; Walther J; Mastrobattista E
    Acc Chem Res; 2019 Jun; 52(6):1555-1564. PubMed ID: 31099553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simplified CRISPR tools for efficient genome editing and streamlined protocols for their delivery into mammalian cells and mouse zygotes.
    Jacobi AM; Rettig GR; Turk R; Collingwood MA; Zeiner SA; Quadros RM; Harms DW; Bonthuis PJ; Gregg C; Ohtsuka M; Gurumurthy CB; Behlke MA
    Methods; 2017 May; 121-122():16-28. PubMed ID: 28351759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of lipid Nanoparticle-Mediated delivery of CRISPR-Cas9 RNP versus mRNA/sgRNA for gene editing in vitro and in vivo.
    Walther J; Porenta D; Wilbie D; Seinen C; Benne N; Yang Q; de Jong OG; Lei Z; Mastrobattista E
    Eur J Pharm Biopharm; 2024 Mar; 196():114207. PubMed ID: 38325664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly Efficient Mouse Genome Editing by CRISPR Ribonucleoprotein Electroporation of Zygotes.
    Chen S; Lee B; Lee AY; Modzelewski AJ; He L
    J Biol Chem; 2016 Jul; 291(28):14457-67. PubMed ID: 27151215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small extracellular vesicles (sEVs)-based gene delivery platform for cell-specific CRISPR/Cas9 genome editing.
    Dubey S; Chen Z; Jiang YJ; Talis A; Molotkov A; Ali A; Mintz A; Momen-Heravi F
    Theranostics; 2024; 14(7):2777-2793. PubMed ID: 38773978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol for Delivery of CRISPR/dCas9 Systems for Epigenetic Editing into Solid Tumors Using Lipid Nanoparticles Encapsulating RNA.
    Woodward EA; Wang E; Wallis C; Sharma R; Tie AWJ; Murthy N; Blancafort P
    Methods Mol Biol; 2024; 2842():267-287. PubMed ID: 39012601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome editing via delivery of Cas9 ribonucleoprotein.
    DeWitt MA; Corn JE; Carroll D
    Methods; 2017 May; 121-122():9-15. PubMed ID: 28410976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas System for Genome Editing: Progress and Prospects as a Therapeutic Tool.
    Sahel DK; Mittal A; Chitkara D
    J Pharmacol Exp Ther; 2019 Sep; 370(3):725-735. PubMed ID: 31122933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering the Delivery System for CRISPR-Based Genome Editing.
    Glass Z; Lee M; Li Y; Xu Q
    Trends Biotechnol; 2018 Feb; 36(2):173-185. PubMed ID: 29305085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing.
    Naeem M; Majeed S; Hoque MZ; Ahmad I
    Cells; 2020 Jul; 9(7):. PubMed ID: 32630835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Packaging and Uncoating of CRISPR/Cas Ribonucleoproteins for Efficient Gene Editing with Viral and Non-Viral Extracellular Nanoparticles.
    Mazurov D; Ramadan L; Kruglova N
    Viruses; 2023 Mar; 15(3):. PubMed ID: 36992399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRIAMF: A New Method for Delivery of Cas9 Ribonucleoprotein Complex to Human Hematopoietic Stem Cells.
    Yen J; Fiorino M; Liu Y; Paula S; Clarkson S; Quinn L; Tschantz WR; Klock H; Guo N; Russ C; Yu VWC; Mickanin C; Stevenson SC; Lee C; Yang Y
    Sci Rep; 2018 Nov; 8(1):16304. PubMed ID: 30389991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA.
    Miller JB; Zhang S; Kos P; Xiong H; Zhou K; Perelman SS; Zhu H; Siegwart DJ
    Angew Chem Int Ed Engl; 2017 Jan; 56(4):1059-1063. PubMed ID: 27981708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field.
    He ZY; Men K; Qin Z; Yang Y; Xu T; Wei YQ
    Sci China Life Sci; 2017 May; 60(5):458-467. PubMed ID: 28527117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide detection of CRISPR editing in vivo using GUIDE-tag.
    Liang SQ; Liu P; Smith JL; Mintzer E; Maitland S; Dong X; Yang Q; Lee J; Haynes CM; Zhu LJ; Watts JK; Sontheimer EJ; Wolfe SA; Xue W
    Nat Commun; 2022 Jan; 13(1):437. PubMed ID: 35064134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring non-viral methods for the delivery of CRISPR-Cas ribonucleoprotein to hematopoietic stem cells.
    Molaei Z; Jabbarpour Z; Omidkhoda A; Ahmadbeigi N
    Stem Cell Res Ther; 2024 Jul; 15(1):233. PubMed ID: 39075609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing.
    Zhang S; Shen J; Li D; Cheng Y
    Theranostics; 2021; 11(2):614-648. PubMed ID: 33391496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
    Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
    Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delivery of the Cas9/sgRNA Ribonucleoprotein Complex in Immortalized and Primary Cells via Virus-like Particles ("Nanoblades").
    Mangeot PE; Guiguettaz L; Sohier TJM; Ricci EP
    J Vis Exp; 2021 Mar; (169):. PubMed ID: 33871447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.